Mereo's $26.1m cash pile hinges on setrusumab filing clarity and alvelestat trial launch

Mereo BioPharma's latest quarterly update leaves its most important commercial question unanswered: whether, and how soon, setrusumab for osteogenesis imperfecta can be submitted for approval. The company, which reported third-quarter 2026 results on 9 November, said it is still in discussions with regulators alongside its partner Ultragenyx. It gave no outcome from those talks and, on the information available, no submission timeline.

The discussions follow the Phase 3 results for setrusumab that were announced in December 2025. Until the filing route is settled, the update offers investors and potential partners little basis for estimating when the asset could reach the market, or what it might be worth to Mereo.

The company's second programme is somewhat more concrete. Mereo and its partner Sentynl are refining the design of a Phase 3 trial of alvelestat in lung disease linked to alpha-1 antitrypsin deficiency (AATD), working through interactions with the US Food and Drug Administration. The companies are aiming to begin the study in early 2027. The final protocol has not been made public.

On the balance sheet, Mereo held $26.1 million in cash at 30 September and expects that to fund operations into late 2027. Its net loss for the quarter narrowed to $5.9 million. The stated runway spans the planned alvelestat start, but the update does not set out how later stages of development would be paid for.